Abstract:With the tremendous increase in viral infection spread and drug resistance, it is imperative to explore new efficient antiviral agents. Two series of novel compounds, triazole-annulated dipyridodiazepines 9(a–e) and methyl-substituted triazole-annulated dipyridodiazepines 10(a–e), were successfully synthesised and characterised by IR, NMR spectroscopy and mass spectrometry. The in vitro reverse transcriptase inhibitory ability of synthesized derivatives was determined using an HIV-1 reverse transcriptase assay kit. Results revealed that 9a and 10a were most potent with an IC 50 of 66 and 71 nM compared with reference drug nevirapine 88nM. A density functional theory (DFT) study of the synthesized compound showed that both triazole series possess noticeably distorted butterfly-like structures, triazole and pyridine rings tilted relative to the diazepine ring and the phenyl ring is perpendicular to the diazepine ring. Significant HOMO/LUMO gap values for both series, 3.71–4.59 eV for the compounds 9(a–e) and 3.69–4.68 eV for compounds 10(a–e) , suggest their quite noticeable stability. Further, these analogues were in silico analysed for molecular docking, drug-likeness, physicochemical and ADMET studies. The good binding scores (high interaction energies) obtained in the molecular docking studies are in good agreement with the molecular electrostatic potential (MEP) analysis results showing accumulations of negative and positive electrostatic potential on different parts of the molecules of the compounds studied. In conclusion, all these results suggest that synthesized analogues could be a potential candidate to inhibit HIV-1 reverse transcriptase and may be considered as lead molecules in the development of new anti-reverse transcriptase agents.

Synthesis and Biological Evaluation of Novel 2-Arylalkylthio-5-iodo-6-benzyl S-DABOs As Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

Synthesis and Biological Evaluation of Novel 2-Arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3h)-ones As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors

Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or Α-Cyanoarylmethyl)-3,4-dihydropyrimidin-4(3h)-ones As Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.

Synthesis and Biological Evaluation of New Conformationally Restricted S-DABO Hybrids As Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.

Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues.

Non‐nucleoside HIV Reverse Transcriptase Inhibitors, Part 6[1]: Synthesis and Anti‐HIV Activity of Novel 2‐[(arylcarbonylmethyl)thio]‐6‐arylthio DABO Analogues

Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.

Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Synthesis and Anti-Hiv Activity Evaluation of 1-[(Alkenyl or Alkynyl or Alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Synthesis and Biological Evaluation of 4-(Hydroxyimino)arylmethyl Diarylpyrimidine Analogues As Potential Non-Nucleoside Reverse Transcriptase Inhibitors Against HIV

Development of novel S -N 3 -DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity

Development of Novel S-N3-DABO Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Potency and Selectivity

Towards New C6-rigid S-DABO HIV-1 Reverse Transcriptase Inhibitors: Synthesis, Biological Investigation and Molecular Modeling Studies

Identification of new triazolo annulated dipyridodiazepine derivatives as HIV-1 reverse transcriptase inhibitors: Design, synthesis, DFT, molecular modelling and in silico studies

Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

Fragment-based Discovery of Sulfur-Containing Diarylbenzopyrimidines As Novel Nonnucleoside Reverse Transcriptase Inhibitors

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Synthesis and Biological Evaluation of Novel 1-Aryl-5-iodo-6-benzyluracils As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors